http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9905261-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5be1d27acf8a63f82dff0177ddaf7fae |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-20 |
| filingDate | 1998-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c24e310588b9eee1336b7765af4e97f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a018c7c473cf2ad1a4e461046c9426d9 |
| publicationDate | 1999-02-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-9905261-A1 |
| titleOfInvention | Monospecific antibody reactive with matrix metalloproteinase cleavage products of fibrin(ogen) |
| abstract | The invention provides a monospecific antibody that is specifically reactive with enzymatically mediated degradation products of fibrin(ogen) (i.e., fibrin, fibrinogen, and related substances). The monospecific antibody of the invention is specifically reactive with an epitope defined by an amino acid sequence SEQ ID NO:1. The invention further provides compositions containing a monospecific antibody, optionally detectably labeled, for the performance of fibrinolytic or thrombolytic analyses. Also provided are kits which include a monospecific antibody metalloproteinase for performing fibrinolytic or thrombolytic analyses. For example, the invention provides a method for detecting fibrin(ogen) degradation products containing the amino acid sequence SEQ ID NO:1 with specificity in biological samples such as blood samples, by using the antibody to immunometrically bind to the peptides. Diagnostic methods for determining information associated with atherogenesis and/or thrombogenesis. The invention further provides continuous cell lines (hybridomas) that produce monospecific antibodies as described. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7094754-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7148194-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7196162-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7071164-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7186693-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7795225-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7189700-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1643958-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1643958-A4 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6906036-B2 |
| priorityDate | 1997-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 541.